Tianjin Xuanhong Pharmaceutical Technology

Tianjin Xuanhong Pharmaceutical Technology is a clinical-stage biopharmaceutical company based in Tianjin, China, specializing in the discovery and development of innovative small molecule therapeutics. Founded in 2018, the company focuses on high-impact therapeutic areas including oncology, metabolic diseases, and immunology. Its lead candidate, XH-001, is a highly selective CDK4/6 inhibitor currently in Phase 1/2 clinical trials for the treatment of advanced breast cancer. The pipeline also includes XH-002, a KRAS G12C inhibitor targeting solid tumors, and XH-008, a URAT1 inhibitor for gout. Xuanhong leverages its internal research capabilities to develop best-in-class drugs that address significant unmet medical needs. The company has successfully raised capital from prominent investors like HighLight Capital to support its clinical programs.